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Background: The aim of our multicenter study was to assess the clinical outcome and safety of ultrasound
(US)-guided high-intensity focused ultrasound (HIFU) in patients with breast fibroadenoma (FA).
Methods: From May 2011 to February 2013, 42 women with 51 FA in one or both breasts were selected for
treatment with US-guided HIFU. Eight of 51 FA were treated twice. Patients’ age ranged from 16 to 52 years (mean
32 years). All patients with FA underwent core needle biopsy with histological confirmation. HIFU treatment was
performed as an outpatient procedure under conscious sedation. Exclusion criteria were pregnant or lactating
women, microcalcifications within the lesion at mammogram, history of breast cancer, previous laser or radiation
therapy, and breast implant in the same breast. All patients signed written informed consent. After the treatment,
follow-up US with volume evaluation was performed at 2, 6, and 12 months.
Results: The FA mean baseline volume was 3.89 ml (0.34–19.66 ml). At 2-month follow-up, the mean volume
reduction was 33.2% ± 19.1% and achieved significance at 6-month (59.2% ± 18.2%, p < 0.001) and 12-month
(72.5% ± 16.7%, p < 0.001) follow-up. Related side effects as superficial skin burn with blister-like aspect in three
patients and hyperpigmentation over the treated area in one patient were transient and resolved spontaneously. In
one patient, asymptomatic subcutaneous induration persisted at the end of the study.
Conclusions: US-guided HIFU treatment is an effective noninvasive method for the treatment of breast FA and
well tolerated by the patients. Preliminary results are encouraging and show that HIFU could be an alternative to
surgery for breast FA.
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Breast fibroadenoma (FA) is a benign tumor, most often
detected during self-examination or clinical breast exam-
ination. Usually occurring in women under the age of 30,
they are seen in approximately 10% of all women during
their lifetime [1,2]. FA account for between 30% and 75%
of all breast biopsies, depending on the age of the popula-
tion being sampled [3]. The widespread implementation* Correspondence: roussanka_kov@yahoo.com
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fact that benign breast diseases represent a growing per-
centage of pathological findings [4].
The most accurate approach to the nonsurgical evalu-
ation of clinically benign dominant breast masses in young
women is the combination of clinical breast examination,
breast imaging studies, and needle biopsy. Used together,
these three modalities are commonly referred to as the
triple test [5]. Ultrasound (US) is the method of choice in
young women, whereas in women over 35, it has to be
combined with mammography. Percutaneous core needle
biopsy (CNB) is the most accurate tool for establishing the
diagnosis [6]. The American Society of Breast Surgeonsntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the diagnostic procedure of choice for US-visible lesions.
Because of its superficial location, breast FA is espe-
cially suitable for minimally invasive ablation techniques.
These techniques can be divided into heat-based modal-
ities, which include high-intensity focused ultrasound
(HIFU), radiofrequency ablation, laser ablation, and tissue-
freezing technique referred to as cryoablation [7-12]. There
are nonthermal ablative techniques as well, like vacuum-
assisted biopsy [13]. US-guided HIFU is a noninvasive
treatment method, without needle or probe insertion into
the target, compared to the most promising image-guided
minimally invasive procedures as vacuum-assisted biopsy
and cryoablation [14,15]. In the last 10 years, the feasibility
and the safety of HIFU have been tested in a number of
clinical studies on benign and malignant tumors of the
prostate, uterus, thyroid gland, parathyroid, liver, kidney,
pancreas, bone, and brain [16-19].
The aim of our multicenter study was to assess the
clinical outcome and safety of US-guided HIFU in pa-
tients with breast FA.
Methods
Study design
The study was performed in four centers—three in
France (American Hospital of Paris, University Hospital
of Lille, and Local Regional Hospital of Valenciennes)
and one in Bulgaria (Sofia University Hospital of Endo-
crinology)—as uncontrolled, open label, and prospective.
Patients over 18 years of age with at least one symptom-
atic breast FA, who met the protocol’s eligibility criteria,
were recruited. The treatment was performed as an out-
patient procedure, and follow-up visits were scheduled
at 1 week, 2 months, 6 months, and 12 months after the
last HIFU treatment. Adverse events during and after
the procedure were evaluated.
Patients
From May 2011 to February 2013, 42 women with 51
FA in one or both breasts were approved for treatment
with US-guided HIFU. In five patients, more than one FA
was selected: two patients with one FA in each breast, two
patients with three FA (two in one breast and one in the
other), and one patient with four FA (three in one breast
and one in the other). Eleven subjects had a personal his-
tory of breast surgery for FA. The patients’ age ranged
from 16 to 52 years (mean 32 years). A formal derogation
was obtained in order to treat one 16-year-old patient.
Selection criteria included female patients ≥18 years
with a palpable and US-visible breast FA, a negative mam-
mogram for microcalcifications in patients over 35 years
of age (Breast Imaging Reporting and Database System
(Bi-RADS) score ≤2), and CNB with histological confirm-
ation for FA by two independent readers. The technicalcriteria included the following: 1) FA size and distance be-
hind the focal point ≥10 mm, to eliminate exteriorization
of the focal energy and damage of vulnerable structures
behind it; 2) distance between the skin and the FA anterior
border ≥5 mm, to prevent skin burn; and 3) distance be-
tween the skin and the FA posterior border ≤23 mm, as a
limit of accessibility for treatment with HIFU. These
criteria had to be reached under treatment conditions,
with an immobilized and potentially compressed breast.
Patients with microcalcifications at mammogram and Bi-
RADS score >2, history of breast cancer, previous laser or
radiation therapy to the same breast, breast implants and
pregnant or lactating women were excluded. FA located
behind the nipple were also excluded if there was no
technical possibility to avoid the nipple. The study was ap-
proved by the local ethics committees, and written in-
formed consent was obtained from all patients.
Imaging evaluation
FA visualization was performed with high-resolution
real-time ultrasonography and color Doppler, using a
7.5- to 10-MHz linear transducer. The FA size was mea-
sured in two orthogonal planes—radial to the nipple and
antiradial—and the volume was calculated according to
the following formula: length × width × depth × π/6. As-
sessment of US characteristics like echogenicity (defined
as anechoic, hypoechoic, isoechoic, and hyperechoic,
related to the normal breast parenchyma), presence of
macrocalcifications, and type of vascularization (periph-
eral and central, qualified as present or absent) was per-
formed. FA localization was documented clock face.
After the HIFU treatment, physical examination was per-
formed at 1 week and US follow-up at 2, 6, and 12 months
to evaluate the changes of volume, echogenicity, and
vascularization. In cases of volume reduction ≤50% and/or
persisting symptoms after the 3-month visit, a second
HIFU treatment was performed with the same follow-up.
Equipment
The treatment was performed with an US-guided HIFU
system, CE marked for this indication (EchoPulse,
Theraclion, Paris, France) (Figure 1). The energy was
delivered via an extra-corporal treatment probe which
includes an imaging system (visualization treatment
unit, VTU) (Figure 2). The high-intensity US waves propa-
gated through the skin and were focused on a portion of
the target tissue, generating rise of heat to therapeutic
levels and causing thermal tissue ablation within the fo-
cused area (Figure 3). The HIFU-induced tissue changes
were visible as hyperechoic marks. HIFU energy was deliv-
ered by the VTU device, which moved automatically over
the defined treatment volume. As a result of the thermal
damage, subsequent fibrosis and volume shrinkage devel-
oped, without effect on the surrounding parenchyma.
Figure 1 External view of the US-guided HIFU equipment.
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The treatment session consisted of five steps: pretreat-
ment ultrasonography, positioning, planning, energy
setting, and treatment with HIFU pulses in the defined
volume.Figure 2 Visualization treatment unit (VTU) components and
principles of function.The patient was placed in lateral decubitus position,
depending on the site of the targeted FA, with the arm
positioned over the patient’s head. The breast was then
immobilized with a specially designed mechanical device
(Theraclion, Paris, France), and the patient was adminis-
tered intravenously fentanyl or midazolam in combin-
ation with propofol to achieve conscious sedation. If the
patient still had pain, a ketoprofen infusion was add-
itionally applied.
The physician outlined the FA on consecutive sections
in radial and antiradial US scans and defined the position
of the focal zone relative to the FA center (Figure 4A).
Thereafter, the number of the treatment units and the
time for treatment were automatically calculated, and the
procedure started with a preselected energy level. DuringFigure 3 Positioning of the treatment device (VTU) over the
targeted fibroadenoma.
Figure 4 Touch screen interface of US-guided HIFU system. (A) The FA is outlined in radial US scan, and the planned treatment units are
displayed on the screen. (B) Hyperechoic mark is visible at the point of the treatment cone after the sonication.
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order to obtain hyperechoic marks on the US image as an
indirect sign of thermal tissue damage (Figure 4B). Then,
the procedure continued with repeated HIFU pulses to
cover the whole treatment volume, under the physician’s
control. The duration of the HIFU session depended on
the FA size. At the end of the treatment, US examination
with a color Doppler was performed.
After the procedure, all patients remained for at least
2 h in a recovery room to be monitored for posttreat-
ment pain or side effects. An iced pad was placed over
the treated FA; ibuprofen one or two tablets per day was
recommended in case of pain in the next 24–48 h.
The patients were evaluated for side effects occurring
during and after the treatment. Pain was assessed at the
end of the procedure, using a 0- to 100-mm visual ana-
log scale (VAS). A questionnaire about discomfort and
pain related to the FA before and after the treatment
was completed by all patients.
The effect of HIFU treatment was evaluated according
to the changes in FA volume and improvement in clin-
ical symptoms, including size by palpation and cosmetic
concerns compared to baseline.
Statistical analysis
All statistical analyses were carried out using SAS®
version 9.2 under the Windows® 2008 terminal. A mixedmodel (MIXED procedure, SAS®) was used to estimate
breast FA volume reduction at 6 and 12 months, and a
logistic model (GLIMMIX procedure, SAS®) was used to
assess the rate of successful volume reduction from baseline
to 6 and 12 months. The relation between energy parame-
ters and volume reduction was examined using Pearson
correlations and mixed models. For subjects who under-
went a second HIFU treatment, a generalized linear model
(GLM procedure, SAS®) was used to estimate the rate of
volume reduction from baseline obtained before and after
the second HIFU treatment.
All models take into account possible multiple breast
FA within subjects. All statistical tests were two sided at
an alpha level of 0.05.
Results
Forty-three FA (84.3%) were treated with a single HIFU
procedure. The patient with four FA and one of the patients
with three FA were treated in two sessions: one session for
the lumps in the same breast, which were neighboring and
up to 20 mm in size, and a second session for the lump in
the other breast. All the other multiple lumps, found in one
patient, were treated in separate sessions.
Eight FA (15.7%) underwent a second HIFU treatment
between the 3-month and 9-month follow-up. The aver-
age treatment duration was 118 min, ranging from 60 to
255 min.
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19.66 ml). At 2-month follow-up, the mean volume re-
duction was 33.2% ± 19.1% and achieved significance at
6-month (59.2% ± 18.2%, p < 0.001) and 12-month (72.5% ±
16.7%, p < 0.001) follow-up (Figure 5). A volume decrease
of 30% at 2-month, 50% at 6-month, and 60% at 12-month
follow-up was present in 63% (29/46), 67% (32/48), and
87% (40/46) of cases, respectively (Figure 6).
At baseline US, the echogenicity was hypoechoic in
90%, anechoic in 4%, hyperechoic in 2%, and complex in
4% of FA. No significant change in the echogenicity was
observed during the follow-up. Color Doppler signals
were absent in 39% of FA at baseline. Two months after
HIFU treatment, vascularization was absent in 54% of
FA and this percentage increased up to 64% and 67% at
6-month and 12-month follow-up, respectively.
All but one patient (98%) were presenting a palpable
breast mass. Discomfort due to the FA was mentioned
in 31 cases (60.8%), which include 15 cases (29.4%) with
discomfort during daily activities, ten cases (19.6%) dur-
ing sports activities, and six cases (11.8%) during profes-
sional activities. Pain related to FA was documented in
18 cases (35.3%). The cosmetic appearance was modified
in ten cases (19.6%), and anxiety due to the presence of
FA was reported in 29 cases (56.9%). A continuous re-
duction in the discomfort in daily activities, perceived by
the patients, was observed during the follow-up period
and completely disappeared in all cases after 12 months
(Figure 7). Pain related to the FA at baseline progres-
sively decreased through the follow-up and totally disap-
peared (Figure 8).
Safety evaluation
All the patients tolerated well the HIFU treatment, and























Figure 5 Percentage of fibroadenoma volume reduction during the foThe mean VAS score was 29.7 ± 27.5 mm (range 0–
80 mm), and no one needed analgesic drugs immediately
after the treatment. Superficial skin burn with blister-
like aspect in three cases (5.9%) and hyperpigmentation
over the treated skin area in one case (2%) were described.
In one case, a palpable subcutaneous induration between
the FA and the skin was found. The changes were of
moderate severity, without symptoms, and no treatment
was administrated. All side effects were transient and
resolved spontaneously, with the exception of the case
with subcutaneous induration, which persisted at the
end of the study.
Discussion
HIFU is an emerging noninvasive method of targeted
thermal ablation. Hynynen et al. were the first to describe
the results of magnetic resonance (MR)-guided HIFU
treatment of breast FA, which was successful in 73% of
the cases, with a significant decrease of the mean FA vol-
ume from 1.9 ml ± 1.5 (SD) to 1.3 ml ± 1.1 (p = 0.01) [17].
They concluded that the treatment was both feasible and
safe without marked adverse events.
In this study, we have described the first follow-up of
US-guided HIFU ablation of breast FA with significant
volume reduction at 6 and 12 months after the treatment.
Our results also demonstrated the advantages of US guid-
ance of all treatment steps—visualization of the target,
positioning, planning, and treatment control. The US im-
aging modality, using the same form of energy as for
HIFU therapy, provided the benefit of a high-resolution
and real-time image for planning and treatment control
[16]. The visibility of HIFU-induced tissue changes as
hyperechoic marks allowed monitoring of the treatment
efficacy. MR has the advantage of temperature quantifica-
tion and the ability to immediately evaluate the treatmentM6 Last
visit
e [months]
llow-up after US-guided HIFU treatment.
Figure 6 Grey-scale US images of two breast fibroadenomas in antiradial scan, before and 12 months after US-guided HIFU treatment.
(A) A 24-year-old female patient with right breast FA at 2 o’clock and with 2.96 ml of initial volume. (B) Twelve months after a single HIFU
treatment; 62.3% of volume reduction was obtained. (C) Right breast FA at 7 o’clock, with 8.14 ml of initial volume in the same patient.
(D) Twelve months after two HIFU treatments; the FA volume reduced by 73.5%.
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and of lower spatial resolution in some cases [16].
Traditionally, symptomatic FA were treated by surgical
excision [4]. However, there is increasing evidence that a



















Figure 7 Percentage of subjects without discomfort in daily activities
M2 2 months, M6 6 months.of FA will disappear without treatment, and the other le-
sions either increase in size or remain unchanged [6,21].
Clinically benign FA can be bothersome to some patients,
causing physical deformity, discomfort, and/or emotional
distress; most breast surgeons will comply with an informedM6 Last
visit
me [months]
















Figure 8 Percentage of subjects without pain related to the fibroadenoma before and after US-guided HIFU treatment. BL baseline, D7
7 days, M2 2 months, M6 6 months.
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open surgical excision which is often performed for clinical
symptoms or for the fear of malignancy [22].
Complications after surgery might be bleeding, wound
infection, an unsatisfactory cosmetic result, and even
recurrence. These side effects could compromise quality
of life [3].
Regarding the benign nature of FA, an important treat-
ment goal should be cosmesis [23]. The minimally invasive
techniques as vacuum-assisted percutaneous excisional
biopsy and percutaneous thermoablation with radiofre-
quency, or cryotherapy are promising for effective and safe
treatment with acceptable cosmetic results [11,14,24].
However, Grady et al. reported up to 33% recurrence rate
after vacuum-assisted excision of larger FA and longer
follow-up [22], whereas US-guided HIFU is a completely
noninvasive procedure, without skin incision and needle
or probe insertion in the breast [17,19,25]. Scar formation
and breast volume loss are avoided as side effects [23]. In
1-year follow-up, FA volume decreased or remained stable,
without US data of regrowth. The rare cases of undiag-
nosed malignancy within a FA [26] should not be an argu-
ment against HIFU treatment, because the tumors are
usually small, mainly in situ, and could be ablated together
with the FA.
Another advantage of HIFU is the ability to reduce
symptoms. Pain and discomfort related to FA at baseline
were completely resolved at the time of the last assess-
ment. Beyond the volume reduction, the most important
aspect for the patient is the disappearance of FA percep-
tion, echoed by the signs and symptoms reduction. Pa-
tient satisfaction of the treatment was also demonstrated
by the willingness of several patients to repeat the treat-
ment for another FA in the same or in the contralateral
breast.Important factors in the global assessment of HIFU
treatment are the hospital stay and the recovery duration.
US-guided HIFU of breast FA is an outpatient procedure,
performed under conscious sedation or perhaps with local
anesthesia, and hence reduces costs incurred by surgical
procedures with general anesthesia.
Conclusions
We have shown the clinical outcome and safety of US-
guided HIFU in patients with breast FA. Our results
demonstrated that the method is effective in reducing the
volume and clinical symptoms of FA without serious side
effects. US-guided HIFU may become a noninvasive alter-
native to surgery. Further studies with longer follow-up
are needed to establish the optimal treatment protocol
and to assess the long-term efficacy.
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